Richard G Jarman Selected Research

Dengue (Dengue Fever)

1/2022	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand.
10/2021	Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies.
1/2021	Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
1/2021	Correlation between reported dengue illness history and seropositivity in rural Thailand.
1/2021	A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain.
1/2021	Precision Tracing of Household Dengue Spread Using Inter- and Intra-Host Viral Variation Data, Kamphaeng Phet, Thailand.
1/2021	Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial.
1/2020	Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.
1/2020	Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study.
1/2020	Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard G Jarman Research Topics

Disease

45	Dengue (Dengue Fever) 01/2022 - 04/2007
38	Infections 01/2021 - 04/2007
8	Human Influenza (Influenza) 01/2018 - 06/2010
7	Viremia 01/2020 - 03/2008
7	Fever (Fevers) 12/2013 - 03/2008
4	Zika Virus Infection 10/2018 - 10/2016
3	Severe Dengue 09/2015 - 04/2007
2	Japanese Encephalitis 01/2020 - 09/2013
2	Yellow Fever 01/2020 - 01/2018
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2017 - 10/2011
2	Coinfection 09/2015 - 04/2007
2	Virus Diseases (Viral Diseases) 08/2014 - 07/2009
2	Acute Febrile Encephalopathy 09/2013 - 07/2012
1	Rabies (Hydrophobia) 01/2020
1	Asymptomatic Infections 12/2018
1	Tick-Borne Encephalitis (Encephalitis, Tick Borne) 01/2018
1	Convalescence 10/2016
1	Lacerations 11/2014
1	Wounds and Injuries (Trauma) 11/2014
1	Leptospirosis 11/2014
1	Necrosis 08/2014
1	Meningitis 07/2012
1	Central Nervous System Infections (Central Nervous System Infection) 07/2012
1	Chickenpox 08/2011

Drug/Important Bio-Agent (IBA)

25	VaccinesIBA 01/2022 - 03/2008
13	Immunoglobulin M (IgM)IBA 04/2020 - 11/2007
11	Neutralizing AntibodiesIBA 01/2022 - 03/2008
9	Dengue VaccinesIBA 01/2022 - 01/2016
9	AntibodiesIBA 04/2020 - 11/2007
9	ImmunosorbentsIBA 01/2018 - 11/2007
9	EnzymesIBA 01/2018 - 11/2007
8	Immunoglobulin G (IgG)IBA 04/2020 - 11/2007
8	AntigensIBA 10/2016 - 01/2008
7	RNA (Ribonucleic Acid)IBA 01/2021 - 07/2009
5	Inactivated VaccinesIBA 01/2020 - 04/2015
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2016 - 11/2007
3	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2016 - 01/2013
2	EpitopesIBA 04/2020 - 09/2015
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2016
2	Antiviral Agents (Antivirals)IBA 01/2018 - 01/2016
2	Viral RNAIBA 01/2018 - 03/2009
2	ProteomeIBA 01/2018 - 09/2015
2	ChitosanIBA 09/2015 - 03/2015
2	NanovaccinesIBA 09/2015 - 03/2015
1	CYD-TDV vaccineIBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	Subunit VaccinesIBA 10/2021
1	NucleotidesIBA 01/2021
1	Immunoglobulin A (IgA)IBA 04/2020
1	Japanese Encephalitis VaccinesIBA 01/2020
1	Broadly Neutralizing AntibodiesIBA 01/2020
1	micaIBA 01/2020
1	mesoglycanIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 12/2018
1	Chemokine CCL5IBA 12/2018
1	Interleukin-12 (IL 12)IBA 12/2018
1	CytokinesIBA 12/2018
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2018
1	Interleukin-6 (Interleukin 6)IBA 12/2018
1	Interleukin-15 (Interleukin 15)IBA 12/2018
1	TeratogensIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	aluminum sulfate (alum)IBA 06/2017
1	Aluminum Hydroxide (Algeldrate)FDA Link 06/2017
1	AS03 adjuvantIBA 06/2017
1	DNA (Deoxyribonucleic Acid)IBA 10/2016
1	Immunoglobulin D (IgD)IBA 10/2016
1	HLA-B44 AntigenIBA 09/2015
1	feralIBA 09/2015
1	Doxycycline (Periostat)FDA LinkGeneric 11/2014
1	Complement System Proteins (Complement)IBA 10/2014
1	3-nitrotyrosineIBA 08/2014
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 08/2014
1	Fc Receptors (Fc Receptor)IBA 05/2012
1	Blocking AntibodiesIBA 05/2012
1	Neurofibromin 2 (Merlin)IBA 12/2011
1	ORALIT (ORS)IBA 07/2011
1	Pharmaceutical PreparationsIBA 07/2011
1	4- (2- (4- isopropylbenzamido)ethoxy)benzoic acidIBA 01/2011
1	STAT1 Transcription FactorIBA 10/2009
1	InterferonsIBA 10/2009
1	Blood Group Antigens (Blood Groups)IBA 04/2007
1	ABO Blood-Group SystemIBA 04/2007

Therapy/Procedure

1	Therapeutics 01/2021